Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.57 |
| ▸ | F10 | P00742 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7435413 | 0.86 | F2 (0.74) | F2F10PRSS2CTRC | |
| SCHEMBL6552973 | 0.86 | F2 (0.52) | F2F10MAOBMAOACTRC | |
| SCHEMBL6554419 | 0.84 | F2 (0.81) | F2F10CTRC | |
| Hydrochloric Acid SCHEMBL6554415 | 0.83 | F2 (0.80) | F2F10CTRC | |
| SCHEMBL6554508 | 0.80 | F2 (0.49) | F2F10PRSS2CTRC | |
| SCHEMBL196710 | 0.79 | TDP1 (0.52) | F2F10PRSS2CTRC | |
| SCHEMBL30217935 | 0.79 | TDP1 (0.52) | F2F10PRSS2CTRC | |
| SCHEMBL7447142 | 0.77 | F2 (0.46) | F2F10PRSS2CTRC | |
| SCHEMBL31487931 | 0.77 | MAOB (0.63) | MAOBARMAOANR4A2MGLL | |
| SCHEMBL27635587 | 0.77 | MAOB (0.63) | MAOBARMAOANR4A2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883405-B1 | AMIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-0859607-B1 | GUANIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6414020-B2 | ANTIPROTEOLYTIC AMIDINO OR DERIVATIVE USEFUL FOR TREATING PENCREATITIS, THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS, EMPHYSEMA OR INFLAMMATION | 3- DIMENSIONAL PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20010025041-A1 | Amidino protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-27 | — | — | US | disclosed |
| US-6281206-B1 | AMIDINO AND BENZAMIDINO COMPOUNDS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | disclosed |
| US-6225302-B1 | Amidino protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-01 | — | — | US | disclosed |
| US-6133315-A | ADMINISTERING TO TREAT PANCREATITIS, THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS, EMPHYSEMA OR INFLAMMATION IN A MAMMAL; COMPOUNDS SUCH AS 2-CHLOROBENZENESULFONIC ACID 3-(3-AMIDINOPROPOXY)-5-METHYLPHENYL ESTER HYDROCHLORIDE | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6034127-A | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0859607-A4 | GUANIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0883405-A4 | AMIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0883405-A1 | AMIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0859607-A1 | GUANIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-08-26 | — | — | EP | disclosed |
| US-5792769-A | POTENT ANTICOAGULANT, ANTIINFLAMMATORY AGENT; TREATMENT/PROPHYLAXIS OF RESPIRATORY SYSTEM DISORDERS, VASCULAR SYSTEM DISORDERS, ANTITUMOR AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1997024135-A1 | AMIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997011693-A1 | GUANIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025041-A1 | Amidino protease inhibitors | CTRL, PEPD, PRSS3 | F2 154/4885F10 296/4885MAOB 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.